Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Panelists discuss how stakeholders can enhance biosimilar uptake through coordinated efforts in financial alignment, patient-centric pricing, professional education, simplified administrative ...

Artificial intelligence (AI) image and upscaler tools provide a great way to enhance ... In addition to its sophisticated HD upscaler, PromeAI includes a variety of other functions tailored to diverse ...

Clarity is a midpoint between a vanilla-style texture pack and an HD reimagining. While all its handmade textures have additional levels of detail, that increased fidelity doesn't come at the cost ...

Image processing is manipulation of an image that has been digitised and uploaded into a computer. Software programs modify the image to make it more useful, and can for example be used to enable ...

Happy Maha Shivratri 2025 Wishes Images, Messages, Status, Photos, Quotes: Maha Shivratri, or the “Great Night of Shiva,” is a significant Hindu festival celebrated by people in India, Nepal, and ...

May his divine light guide you always." People also share images related to Lord Shiva and the festival. "When you trust Lord Shiva, everything falls into place." "Shivratri is not just about praying; ...

Google Photos functions a lot like a Gallery app. You can view your photos and videos from within the app, share them with others, download pictures, and upload ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...